Search

Your search keyword '"Xu, Jian-Ming"' showing total 633 results
Start Over Author "Xu, Jian-Ming"
633 results on '"Xu, Jian-Ming"'

107. Circulating tumor DNA clone analysis to predict disease progression/indicates trastuzumab-resistant mechanism in advanced gastric cancer.

Author

Wang, Yan, primary, Chang, Lianpeng, additional, Jiang, Yu-Bo, additional, Jia, Ru, additional, Chen, Rongrong, additional, Li, Jin, additional, Xia, Xuefeng, additional, Guan, Yan-Fang, additional, Liu, Rongrui, additional, Zhao, Chuanhua, additional, Zhang, Yun, additional, Yi, Xin, additional, and Xu, Jian-Ming, additional

Published
2018
Full Text
View/download PDF

108. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.

Author

Bai, Yu-Xian, primary, Qin, Shukui, additional, Li, Jin, additional, Deng, Yanhong, additional, Yang, Lei, additional, Xu, Rui-hua, additional, Zhong, Haijun, additional, Chen, Zhendong, additional, Pan, Hongming, additional, Guo, Weijian, additional, Shu, Yongqian, additional, Peng, Cike, additional, Chen, Yun, additional, Li, Hongyan, additional, Wang, Ning, additional, Guo, Xiaojun, additional, Wang, Wei, additional, Fan, Songhua, additional, Xu, Jian-Ming, additional, and Shen, Lin, additional

Published
2018
Full Text
View/download PDF

111. Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.

Author

Wang, Feng, primary, Liu, Tian Shu, additional, Yuan, Xianglin, additional, Gu, Kangsheng, additional, Yuan, Ying, additional, Deng, Yanhong, additional, Xu, Jian-Ming, additional, Bai, Yu-Xian, additional, Wang, Ying, additional, Liao, Wangjun, additional, Zhang, He-Long, additional, Bi, Feng, additional, Wang, Bang-Mao, additional, Zhuang, Zhixiang, additional, Luo, Huiyan, additional, and Xu, Rui-hua, additional

Published
2018
Full Text
View/download PDF

113. Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.

Author

Xu, Jian-Ming, primary, Zhang, Yun, additional, Jia, Ru, additional, Wang, Yan, additional, Liu, Rongrui, additional, Zhang, Gairong, additional, Zhao, Chuanhua, additional, Zhang, Yaoyue, additional, Zou, Jianjun, additional, and Wang, Quanren, additional

Published
2018
Full Text
View/download PDF

115. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

Author

UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Raymond, Eric, Kulke, Matthew H., Qin, Shukui, Yu, Xianjun, Schenker, Michael, Cubillo, Antonio, Lou, Wenhui, Tomasek, Jiri, Thiis-Evensen, Espen, Xu, Jian-Ming, Croitoru, Adina E., Khasraw, Mustafa, Sedlackova, Eva, Borbath, Ivan, Ruff, Paul, Oberstein, Paul E., Ito, Tetsuhide, Jia, Liqun, Hammel, Pascal, Shen, Lin, Shrikhande, Shailesh V., Shen, Yali, Sufliarsky, Jozef, Khan, Gazala N., Morizane, Chigusa, Galdy, Salvatore, Khosravan, Reza, Fernandez, Kathrine C., Rosbrook, Brad, Fazio, Nicola, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Raymond, Eric, Kulke, Matthew H., Qin, Shukui, Yu, Xianjun, Schenker, Michael, Cubillo, Antonio, Lou, Wenhui, Tomasek, Jiri, Thiis-Evensen, Espen, Xu, Jian-Ming, Croitoru, Adina E., Khasraw, Mustafa, Sedlackova, Eva, Borbath, Ivan, Ruff, Paul, Oberstein, Paul E., Ito, Tetsuhide, Jia, Liqun, Hammel, Pascal, Shen, Lin, Shrikhande, Shailesh V., Shen, Yali, Sufliarsky, Jozef, Khan, Gazala N., Morizane, Chigusa, Galdy, Salvatore, Khosravan, Reza, Fernandez, Kathrine C., Rosbrook, Brad, and Fazio, Nicola

Abstract

BACKGROUND: In a phase III study, sunitinib led to a significant increase in progression-free survival (PFS) versus placebo in patients with pancreatic neuroendocrine tumours (panNETs). This study was a post-marketing commitment to support the phase III data. METHODS: In this ongoing, open-label, phase IV trial (NCT01525550), patients with progressive, advanced unresectable/metastatic, well-differentiated panNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were similar to those of the phase III study. The primary endpoint was investigator-assessed PFS per Response Evaluation Criteria in Solid Tumours v1.0 (RECIST). Other endpoints included PFS per Choi criteria, overall survival (OS), objective response rate (ORR), and adverse events (AEs). RESULTS: Sixty-one treatment-naive and 45 previously treated patients received sunitinib. By March 19, 2016, 82 (77%) patients had discontinued treatment, mainly due to disease progression. Median treatment duration was 11.7 months. Investigator-assessed median PFS per RECIST (95% confidence interval [CI]) was 13.2 months (10.9-16.7): 13.2 (7.4-16.8) and 13.0 (9.2-20.4) in treatment-naive and previously treated patients, respectively. ORR (95% CI) per RECIST was 24.5% (16.7-33.8) in the total population: 21.3% (11.9-33.7) in treatment-naive and 28.9% (16.4-44.3) in previously treated patients. Median OS, although not yet mature, was 37.8 months (95% CI, 33.0-not estimable). The most common treatment-related AEs were neutropenia (53.8%), diarrhoea (46.2%), and leukopenia (43.4%). CONCLUSIONS: This phase IV trial confirms sunitinib as an efficacious and safe treatment option in patients with advanced/metastatic, well-differentiated, unresectable panNETs, and supports the phase III study outcomes. AEs were consistent with the known safety profile of sunitinib.

Published
2018

116. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

Author

Zhou, Jian, primary, Sun, Hui-Chuan, additional, Wang, Zheng, additional, Cong, Wen-Ming , additional, Wang, Jian-Hua, additional, Zeng, Meng-Su, additional, Yang, Jia-Mei, additional, Bie, Ping, additional, Liu, Lian-Xin, additional, Wen, Tian-Fu, additional, Han, Guo-Hong, additional, Wang, Mao-Qiang, additional, Liu, Rui-Bao, additional, Lu, Li-Gong, additional, Ren, Zheng-Gang, additional, Chen, Min-Shan, additional, Zeng, Zhao-Chong, additional, Liang, Ping, additional, Liang, Chang-Hong, additional, Chen, Min, additional, Yan, Fu-Hua, additional, Wang, Wen-Ping, additional, Ji, Yuan, additional, Cheng, Wen-Wu, additional, Dai, Chao-Liu, additional, Jia, Wei-Dong, additional, Li, Ya-Ming, additional, Li, Ye-Xiong, additional, Liang, Jun, additional, Liu, Tian-Shu, additional, Lv, Guo-Yue, additional, Mao, Yi-Lei, additional, Ren, Wei-Xin, additional, Shi, Hong-Cheng, additional, Wang, Wen-Tao, additional, Wang, Xiao-Ying, additional, Xing, Bao-Cai, additional, Xu, Jian-Ming, additional, Yang, Jian-Yong, additional, Yang, Ye-Fa, additional, Ye, Sheng-Long, additional, Yin, Zheng-Yu, additional, Zhang, Bo-Heng, additional, Zhang, Shui-Jun, additional, Zhou, Wei-Ping, additional, Zhu, Ji-Ye, additional, Liu, Rong, additional, Shi, Ying-Hong, additional, Xiao, Yong-Sheng, additional, Dai, Zhi, additional, Teng, Gao-Jun, additional, Cai, Jian-Qiang, additional, Wang, Wei-Lin, additional, Dong, Jia-Hong, additional, Li, Qiang, additional, Shen, Feng, additional, Qin, Shu-Kui, additional, and Fan, Jia, additional

Published
2018
Full Text
View/download PDF

117. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

Author

Raymond, Eric, primary, Kulke, Matthew H., additional, Qin, Shukui, additional, Yu, Xianjun, additional, Schenker, Michael, additional, Cubillo, Antonio, additional, Lou, Wenhui, additional, Tomasek, Jiri, additional, Thiis-Evensen, Espen, additional, Xu, Jian-Ming, additional, Croitoru, Adina E., additional, Khasraw, Mustafa, additional, Sedlackova, Eva, additional, Borbath, Ivan, additional, Ruff, Paul, additional, Oberstein, Paul E., additional, Ito, Tetsuhide, additional, Jia, Liqun, additional, Hammel, Pascal, additional, Shen, Lin, additional, Shrikhande, Shailesh V., additional, Shen, Yali, additional, Sufliarsky, Jozef, additional, Khan, Gazala N., additional, Morizane, Chigusa, additional, Galdy, Salvatore, additional, Khosravan, Reza, additional, Fernandez, Kathrine C., additional, Rosbrook, Brad, additional, and Fazio, Nicola, additional

Published
2018
Full Text
View/download PDF

118. PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Author

Xu, Jian-Ming, primary, Wang, Yan, additional, Wang, You-Liang, additional, Liu, Tao, additional, Ni, Ming, additional, Li, Man-Sheng, additional, Lin, Li, additional, Ge, Fei-Jiao, additional, Gong, Chun, additional, Gu, Jun-Yan, additional, Jia, Ru, additional, Wang, He-Fei, additional, Chen, Yu-Ling, additional, Liu, Rong-Rui, additional, Zhao, Chuan-Hua, additional, Tan, Zhao-Li, additional, Jin, Yang, additional, Zhu, Yun-Ping, additional, Ogino, Shuji, additional, and Qian, Zhi-Rong, additional

Published
2017
Full Text
View/download PDF

121. Treatment patterns, effectiveness, and safety of Trastuzumab in Chinese patients with metastatic gastric cancer: Interim analysis of the EVIDENCE registry study.

Author

Qin, Shukui, primary, Lin, Shen, additional, Xu, Ruihua, additional, Su, Wuyun, additional, Tang, Yong, additional, Wang, Xin, additional, Xu, Jian-ming, additional, Zhou, Weiping, additional, Cui, Tongjian, additional, Luo, Suxia, additional, Wu, Xiaohui, additional, and Ji, Jiafu, additional

Published
2017
Full Text
View/download PDF

122. Computer-assisted diagnosis of early esophageal squamous cell carcinoma using narrow-band imaging magnifying endoscopy.

Author

Zhao, Yuan-Yuan, Xue, Di-Xiu, Wang, Ya-Lei, Zhang, Rong, Sun, Bin, Cai, Yong-Ping, Feng, Hui, Cai, Yi, and Xu, Jian-Ming

Subjects
SQUAMOUS cell carcinoma, TISSUE wounds, ESOPHAGEAL abnormalities
Abstract

Background: We developed a computer-assisted diagnosis model to evaluate the feasibility of automated classification of intrapapillary capillary loops (IPCLs) to improve the detection of esophageal squamous cell carcinoma (ESCC).Methods: We recruited patients who underwent magnifying endoscopy with narrow-band imaging for evaluation of a suspicious esophageal condition. Case images were evaluated to establish a gold standard IPCL classification according to the endoscopic diagnosis and histological findings. A double-labeling fully convolutional network (FCN) was developed for image segmentation. Diagnostic performance of the model was compared with that of endoscopists grouped according to years of experience (senior > 15 years; mid level 10 - 15 years; junior 5 - 10 years).Results: Of the 1383 lesions in the study, the mean accuracies of IPCL classification were 92.0 %, 82.0 %, and 73.3 %, for the senior, mid level, and junior groups, respectively. The mean diagnostic accuracy of the model was 89.2 % and 93.0 % at the lesion and pixel levels, respectively. The interobserver agreement between the model and the gold standard was substantial (kappa value, 0.719). The accuracy of the model for inflammatory lesions (92.5 %) was superior to that of the mid level (88.1 %) and junior (86.3 %) groups (P < 0.001). For malignant lesions, the accuracy of the model (B1, 87.6 %; B2, 93.9 %) was significantly higher than that of the mid level (B1, 79.1 %; B2, 90.0 %) and junior (B1, 69.2 %; B2, 79.3 %) groups (P < 0.001).Conclusions: Double-labeling FCN automated IPCL recognition was feasible and could facilitate early detection of ESCC. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

123. Diffuse alveolar hemorrhage after erlotinib combined with concurrent chemoradiotherapy in a patient with esophageal carcinoma

Author

Zhao, Chuan-Hua, Liu, Rong-Rui, Lin, Li, Liu, Jian-Zhi, Ge, Fei-Jiao, Li, Shan-Shan, Ye, Chen-Yang, Chen, Yu-Ling, Wang, Yan, and Xu, Jian-Ming

Subjects
Case Report, respiratory tract diseases
Abstract

Diffuse alveolar hemorrhage (DAH) is a life-threatening clinical pathologic syndrome caused by a variety of diseases. We report a case of DAH related to combination therapy of chemoradiotherapy and erlotinib. As to know, DAH following chemoradiotherapy was only reported among hematopoietic stem cell transplant recipients with hematologic malignancies till now. DAH associated with chemoradiotherapy for oesophageal carcinoma has not been reported. This is the first DAH report on erlotinib-combined chemoradiotherapy for esophageal cancer. The authors believe epidermal growth factor receptor tyrosine kinase inhibitor erlotinib increased the lung injury. Molecular targeted drugs are gradually applied to be combined with chemoradiation, whether this combination will cause the increase of serious adverse reactions need further study. This case can provide certain reference for erlotinib in the treatment. Meanwhile, after long term hormone therapy for DAH, the patient was diagnosed with pneumocystis carinii pneumonia. It reminds us to attach importance to the immunosuppressive diseases after long-term hormone treatment.

Published
2014

126. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study

Author

Xu, Jian Ming, primary, Wang, Yan, additional, Chen, Yu Ling, additional, Jia, Ru, additional, Li, Jie, additional, Gong, Ji Fang, additional, Li, Jing, additional, Qi, Chuan, additional, Hua, Ye, additional, Tan, Cui Rong, additional, Wang, Jian, additional, Li, Ke, additional, Sai, Yang, additional, Zhou, Feng, additional, Ren, Yong Xin, additional, Qing, Wei Guo, additional, Jia, Hong, additional, Su, Wei Guo, additional, and Shen, Lin, additional

Published
2017
Full Text
View/download PDF

128. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study

Author

Yang, Liu-Qing, primary, Sun, Xin-Chen, additional, Qin, Shu-Kui, additional, Chen, Ying-Xia, additional, Zhang, He-Long, additional, Cheng, Ying, additional, Chen, Zhen-Dong, additional, Shi, Jian-Hua, additional, Wu, Qiong, additional, Bai, Yu-Xian, additional, Han, Bao-Hui, additional, Liu, Wei, additional, Ouyang, Xue-Nong, additional, Liu, Ji-Wei, additional, Zhang, Zhi-Hui, additional, Li, Yong-Qiang, additional, Xu, Jian-Ming, additional, and Yu, Shi-Ying, additional

Published
2016
Full Text
View/download PDF

131. A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).

Author

Tanwandee, Tawesak, primary, Sukeepaisarnjaroen, Wattana, additional, Chan, Stephen Lam, additional, Choo, SuPin, additional, Han, Guohong, additional, Sriuranpong, Virote, additional, Pan, Hongming, additional, Yau, Thomas Cheung, additional, Ren, Zhenggang, additional, Xu, Jian-Ming, additional, Peng, Bin, additional, Saji, Takami, additional, Sun, Yongjian, additional, Huang, Alan, additional, Manenti, Luigi, additional, and Qin, Shukui, additional

Published
2016
Full Text
View/download PDF

132. Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial

Author

Demetri, George D., Reichardt, Peter, Kang, Yoon-Koo, Jean-Yves Blay, Joensuu, Heikki, Maki, Robert G., Rutkowski, Piotr, Hohenberger, Peter, Gelderblom, Hans, Leahy, Michael Gordon, Mehren, Margaret, Schoffski, Patrick, Blackstein, Martin E., Le Cesne, Axel, Badalamenti, Giuseppe, Xu, Jian-Ming, Nishida, Toshirou, Laurent, Dirk, Kuss, Iris, Casali, Paolo Giovanni, and Invest, Grid

Subjects
Cancer Research, Oncology
Abstract

LBA10008 Background: Oral multikinase inhibitor regorafenib (REG) demonstrated substantial activity in a phase II trial in pts with GIST after failure of both IM and SU (J Clin Oncol. 2011; 29:606s; abstr 10007). This phase III, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of REG for this unmet clinical need. Methods: Eligible pts had metastatic and/or unresectable GIST, objective failure of both prior IM and SU (progressive disease [PD] on, or intolerance to, IM and PD on SU), ≥1 measurable lesion, ECOG performance status 0 or 1. Pts were randomized 2:1 to receive best supportive care plus either REG 160 mg po once daily (3 wks on/1 wk off) or placebo (PL). The primary endpoint was progression-free survival (PFS) (modified RECIST 1.1, independent central review). Secondary endpoints included overall survival (OS), disease control rate (DCR, defined as rate of partial response [PR] plus stable disease [SD] lasting for ≥12 wks), response rate and duration, safety and correlative genotype analyses. At time of PD, pts were eligible for unblinding and crossover to open-label REG. Results: Between Jan and Aug of 2011, 234 pts were screened; 199 were randomized (REG: 133, PL: 66). Pts were stratified at randomization according to number of prior systemic therapies and geographical region. Baseline characteristics were balanced between the two arms. The primary endpoint was met: median PFS was 4.8 months for REG vs. 0.9 months for PL. Hazard ratio for PFS was 0.27 (95% CI, 0.18-0.39), p grade 3 treatment-emergent AEs in the REG arm during double-blind study were hypertension (28%), hand-foot skin reaction (21%), and diarrhea (8%). Conclusions: This randomized trial demonstrated that REG significantly improved PFS and DCR in pts with advanced GIST after failure of at least prior IM and SU. REG was well tolerated, with AEs as expected for this class and manageable with dose modifications.

Published
2012

133. Arsenic Reduces Methane Emissions from Paddy Soils: Insights from Continental Investigation and Laboratory Incubations

Author

Jiang, Ou-Yuan, Zhang, Si-Yu, Zhao, Xin-Di, Liu, Zi-Teng, Kappler, Andreas, Xu, Jian-Ming, and Tang, Xian-Jin

Abstract

Arsenic (As) contamination and methane (CH4) emissions co-occur in rice paddies. However, how As impacts CH4production, oxidation, and emission dynamics is unknown. Here, we investigated the abundances and activities of CH4-cycling microbes from 132 paddy soils with different As concentrations across continental China using metagenomics and the reverse transcription polymerase chain reaction. Our results revealed that As was a crucial factor affecting the abundance and distribution patterns of the mcrAgene, which is responsible for CH4production and anaerobic CH4oxidation. Laboratory incubation experiments showed that adding 30 mg kg–1arsenate increased 13CO2production by 10-fold, ultimately decreasing CH4emissions by 68.5%. The inhibition of CH4emissions by As was induced through three aspects: (1) the toxicity of As decreased the abundance and activity of the methanogens; (2) the adaptability and response of methanotrophs to As is beneficial for CH4oxidation under As stress; and (3) the more robust arsenate reduction would anaerobically consume more CH4in paddies. Additionally, significant positive correlations were observed between arsCand pmoAgene abundance in both the observational study and incubation experiment. These findings enhance our understanding of the mechanisms underlying the interactions between As and CH4cycling in soils.

Published
2024
Full Text
View/download PDF

134. Application of Skin Electrical Conductance of Acupuncture Meridians for Ureteral Calculus: A Case Report

Author

Lin, Wu-Chou, Chen, Yung-Hsiang, Xu, Jian-Ming, Chen, Der-Cherng, Chen, Wen-Chi, and Lee, Chao-Te

Subjects
Article Subject
Abstract

Renal colic is a common condition seen in the emergency department (ED). Our recent study showed that measures of electrical conductance may be used as supplementary diagnostic methods for patients with acute renal colic. Here, we describe the case of a 30-year-old male subject with a left ureteral calculus who presented with frequency and normal-looking urine. He had already visited the outpatient department, but in vain. Normal urinalysis and nonobstructive urogram were reported at that time. Two days later, he was admitted to the ED because of abdominal pain in the left lower quadrant. The urinalysis did not detect red blood cells. Ultrasonography did not indicate hydronephrosis. The meridian electrical conductance and index of sympathovagal balance were found to be abnormal. High level of electrical conductance on the left bladder meridian was found. An unenhanced helical computed tomography was scheduled to reveal a left ureterovesical stone. Ureteroscopic intervention was later uneventfully performed, and the patient's pain was relieved. The follow-up measurements showed that the meridian parameters had returned to normal one month after treatment. This case suggests that bladder meridian electrical conductance might be used as a supplemental method for ureteral calculus diagnosis.

Published
2011
Full Text
View/download PDF

135. A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC).

Author

Shen, Lin, primary, Yu, Xianjun, additional, Hao, Jihui, additional, Wang, Liwei, additional, Pan, Hongming, additional, Han, Guohong, additional, Xu, Jian-Ming, additional, Zhang, Yanqiao, additional, Yang, Shujun, additional, Chen, Jia, additional, Ying, Jieer, additional, Dai, Guanghai, additional, Li, Mingyu, additional, Begic, Damir, additional, Lu, Brian D., additional, and Xu, Ruihua, additional

Published
2016
Full Text
View/download PDF

136. Expert consensus on maintenance treatment for metastatic colorectal cancer in China

Author

Xu, Rui-Hua, primary, Shen, Lin, additional, Li, Jin, additional, Xu, Jian-Ming, additional, Bi, Feng, additional, Ba, Yi, additional, Bai, Li, additional, Shu, Yong-Qian, additional, Liu, Tian-Shu, additional, Li, Yu-Hong, additional, Bai, Chun-Mei, additional, Yuan, Xiang-Lin, additional, Zhang, Jun, additional, Chen, Gong, additional, Zhou, Ai-Ping, additional, Yuan, Ying, additional, Wang, Xi-Jing, additional, Qian, Xiao-Ping, additional, and Deng, Yan-Hong, additional

Published
2016
Full Text
View/download PDF

139. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

Author

Azzariti, Amalia, primary, Porcelli, Letizia, additional, Brunetti, Oronzo, additional, Del Re, Marzia, additional, Longo, Vito, additional, Nardulli, Patrizia, additional, Signorile, Michele, additional, Xu, Jian-Ming, additional, Calabrese, Angela, additional, Quatrale, Anna Elisa, additional, Maiello, Evaristo, additional, Lorusso, Vito, additional, and Silvestris, Nicola, additional

Published
2016
Full Text
View/download PDF

146. Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment

Author

Jia, Ru, primary, Wang, Yan, additional, Mao, Xiao‐Yang, additional, Li, Shan‐Shan, additional, Xu, Nong, additional, Xiong, Jian‐Ping, additional, Shen, Lin, additional, Bai, Li, additional, Liu, Wei, additional, Liu, Lie‐Jun, additional, Ge, Fei‐Jiao, additional, Chen, Yu‐Ling, additional, Lin, Li, additional, and Xu, Jian‐Ming, additional

Published
2015
Full Text
View/download PDF

149. Cross-sectional analysis of patients with non-mGC in China: An update of EVIDENCE gastric cancer registry study.

Author

Wang, Xin, primary, Ji, Jiafu, additional, Zheng, Zhichao, additional, Zhang, Helong, additional, Zhou, Weiping, additional, Su, Wuyun, additional, Luo, Qi, additional, Guo, Qunyi, additional, Li, Xiaoyi, additional, Tang, Yong, additional, Xu, Jian-Ming, additional, Tao, Feng, additional, Li, Wei, additional, Li, Xiaoqin, additional, Qin, Shukui, additional, Yu, Eric Chi-Wang, additional, Yang, Chen, additional, and Shen, Lin, additional

Published
2015
Full Text
View/download PDF

150. Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx).

Author

Bang, Yung-Jue, primary, Qin, Shukui, additional, Chung, Hyun-Choel, additional, Xu, Jian-Ming, additional, Park, Joon Oh, additional, Jeziorski, Krzysztof, additional, Shparyk, Yaroslav, additional, Hoff, Paulo M., additional, Sobrero, Alberto F., additional, Salman, Pamela, additional, Li, Jin, additional, Protsenko, Svetlana, additional, Buyse, Marc E., additional, Afenjar, Karen, additional, Houe, Vincent, additional, Garcia, Agathe, additional, Huang, Yingjie, additional, Armour, Alison, additional, Slamon, Dennis J., additional, and Hecht, J. Randolph, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results